Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Complera in Virologically Suppressed HIV-1 Patients
NCT01252940Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Nov 2010; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01252940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252940.